# US 2001/0024826 A1 · Method of preparing an undifferentiated cell

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024826 A1
- Document ID: US20010024826A1
- Status: Published application
- Kind: A1
- Application number: 09/742,520
- Filed: 2000-12-20
- Published: 2001-09-27
- Earliest claimed: 1995-02-02
- Assignees: Ghazi Jaswinder Dhoot
- Inventors: Ilham Saleh Abuljadayel
- Web page: https://patentgrep.com/patent/US20010024826A1

## CPC

- C12N 5/0634: {Cells from the blood or the immune system}
- C12N 2501/06: Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
- C12N 2501/50: Cell markers; Cell surface determinants
- C12N 2506/11: from blood or immune system cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method of preparing an undifferentiated cell is described. The method comprises contacting a more committed cell with an agent that causes the more committed cell to retrodifferentiate into an undifferentiated cell.

## Claims

### Claim 1

A method of preparing an undifferentiated cell, the method comprising contacting a more committed cell with an agent that causes the more committed cell to retrodifferentiate into an undifferentiated cell.

### Claim 2 (depends on 1)

A method according to claim 1 wherein the more committed cell is capable of retrodifferentiating into an MHC Class I+ and/or an MHC Class II+ undifferentiated cell.

### Claim 3 (depends on 1, 2)

A method according to claim 1 or claim 2 wherein the more committed cell is capable of retrodifferentiating into an undifferentiated cell comprising a stem cell antigen.

### Claim 4

A method according to any one of the preceding claims wherein the more committed cell is capable of retrodifferentiating into a CD34+ undifferentiated cell.

### Claim 5

A method according to any one of the preceding claims wherein the more committed cell is capable of retrodifferentiating into a lymphohaematopoietic progenitor cell.

### Claim 6

A method according to any one of the preceding claims wherein the more committed cell is capable of retrodifferentiating into a pluripotent stem cell.

### Claim 7

A method according to any one of the preceding claims wherein the undifferentiated cell is an MHC Class I+ and/or an MHC Class II+ cell.

### Claim 8

A method according to any one of the preceding claims wherein the undifferentiated cell comprises a stem cell antigen.

### Claim 9

A method according to any one of the preceding claims wherein the undifferentiated cell is a CD34+ undifferentiated cell.

### Claim 10

A method according to any one of the preceding claims wherein the undifferentiated cell is a lymphohaematopoietic progenitor cell.

### Claim 11

A method according to any one of the preceding claims wherein the undifferentiated cell is a pluripotent stem cell.

### Claim 12

A method according to any one of the preceding claims wherein the more committed cell is an MHC Class I+ and/or an MHC Class II+ cell.

### Claim 13

A method according to any one of the preceding claims wherein the agent acts extracelluarly of the more committed cell.

### Claim 14

A method according to any one of the preceding claims wherein the more committed cell comprises a receptor that is operably engageable by the agent and wherein the agent operably engages the receptor.

### Claim 15 (depends on 14)

A method according to claim 14 wherein the receptor is a cell surface receptor.

### Claim 16 (depends on 14, 15)

A method according to claim 14 or claim 15 wherein the receptor comprises an α-component and/or a β-component.

### Claim 17 (depends on 16)

A method according to claim 16 wherein the receptor comprises a β-chain having homologous regions.

### Claim 18 (depends on 17)

A method according to claim 17 wherein the receptor comprises at least the homologous regions of the β-chain of HLA-DR.

### Claim 19 (depends on 16)

A method according to claim 16 wherein the receptor comprises an α-chain having homologous regions.

### Claim 20 (depends on 19)

A method according to claim 19 wherein the receptor comprises at least the homologous regions of the α-chain of HLA-DR.

### Claim 21 (depends on 14, 15, 16, 17, 18, 19, 20)

A method according to any one of claims 14 to 20 wherein the agent is an antibody to the receptor.

### Claim 22 (depends on 21)

A method according to claim 21 wherein the agent is a monoclonal antibody to the receptor.

### Claim 23 (depends on 18)

A method according to claim 18 wherein the agent is an antibody, preferably a monoclonal antibody, to the homologous regions of the β-chain of HLA-DR.

### Claim 24 (depends on 20)

A method according to claim 20 wherein the agent is an antibody, preferably a monoclonal antibody, to the homologous regions of the α-chain of HLA-DR.

### Claim 25

A method according to any one of the preceding claims wherein the agent modulates MHC gene expression, preferably wherein the agent modulates MHC Class I+ and/or MHC Class II+ expression.

### Claim 26

A method according to any one of the preceding claims wherein the agent is used in conjunction with a biological response modifier.

### Claim 27 (depends on 25)

A method according to claim 25 wherein the biological response modifier is an alkylating agent, preferably wherein the alkylating agent is or comprises cyclophosphoamide.

### Claim 28

A method according to any one of the preceding claims wherein the more committed cell is a differentiated cell.

### Claim 29 (depends on 28)

A method according to claim 28 wherein the more committed cell is any one of a B cell or a T cell.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

A method according to any one of claims 1 to 27 wherein the more committed cell is a more mature undifferentiated cell.

### Claim 31

A method according to any one of the preceding claims wherein the undifferentiated cell is committed to a recommitted cell.

### Claim 32 (depends on 31)

A method according to claim 31 wherein the recommitted cell is of the same lineage as the more committed cell prior to retrodifferentiation.

### Claim 33 (depends on 31)

A method according to claim 31 wherein the recommitted cell is of a different lineage as the more committed cell prior to retrodifferentiation.

### Claim 34 (depends on 31, 32, 33)

A method according to any one of claims 31 to 33 wherein the recommitted cell is any one of a B cell, a T cell or a granulocyte.

### Claim 35

A method according to any one of the preceding claims wherein the method is an in vitro method.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

An undifferentiated cell produced according to the method of any one of claims 1 to 35.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

An undifferentiated cell produced according to the method of any one of claims 1 to 35 for use as or in the preparation of a medicament.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

Use of an undifferentiated cell produced according to the method of any one of claims 1 to 37 in the manufacture of a medicament for the treatment of an immunological disorder or disease.

### Claim 39 (depends on 31, 32, 33, 34, 35)

A recommitted cell produced according to the method of any one of claims 31 to 35.

### Claim 40 (depends on 31, 32, 33, 34, 35)

A recommitted cell produced according to the method of any one of claims 31 to 35 for use as or in the preparation of a medicament.

### Claim 41 (depends on 31, 32, 33, 34, 35)

Use of a recommitted cell produced according to the method of any one of claims 31 to 35 in the manufacture of a medicament for the treatment of an immunological disorder or disease.

### Claim 42

A more committed cell having attached thereto an agent that can cause the more committed cell to retrodifferentiate into an undifferentiated cell.

### Claim 43

A CD19+ and CD3+ cell.

### Claim 44

A method of preparing an undifferentiated cell from a more committed cell substantially as hereinbefore described.

### Claim 45

An undifferentiated cell prepared from a more committed cell substantially as hereinbefore described.

### Claim 46

A recommitted cell prepared from an undifferentiated cell which has been prepared from a more committed cell substantially as hereinbefore described.
